RESPONSE TO 3RD-LINE ENDOCRINE TREATMENT FOR ADVANCED BREAST-CANCER

被引:14
作者
IVESON, TJ [1 ]
AHERN, J [1 ]
SMITH, IE [1 ]
机构
[1] ROYAL MARSDEN HOSP,BREAST UNIT,FULHAM RD,LONDON SW3 6JJ,ENGLAND
关键词
D O I
10.1016/S0959-8049(05)80154-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a retrospective analysis we have identified 55 patients who have received three endocrine treatments for advanced breast cancer. 42% of these patients have benefitted from third-line endocrine treatment in terms of disease stabilisation, symptom relief or objective response and this was translated into statistically significant (P<0.01) improved median survival of these patients (34 months) compared with those with progressive disease on third-line treatment (14 months). This suggests that third-line endocrine treatment might be of benefit to a number of patients with advanced breast cancer.
引用
收藏
页码:572 / 574
页数:3
相关论文
共 25 条
[21]  
Santen R J, 1981, Breast Cancer Res Treat, V1, P183, DOI 10.1007/BF01806259
[22]  
SCHACTER LP, 1990, SEMIN ONCOL, V17, P38
[23]   TAMOXIFEN VERSUS AMINOGLUTETHIMIDE IN ADVANCED BREAST-CARCINOMA - A RANDOMIZED CROSSOVER TRIAL [J].
SMITH, IE ;
HARRIS, AL ;
MORGAN, M ;
FORD, HT ;
GAZET, JC ;
HARMER, C ;
WHITE, H ;
PARSONS, CA ;
VILLARDO, A ;
WALSH, G ;
MCKINNA, JA .
BRITISH MEDICAL JOURNAL, 1981, 283 (6304) :1432-1434
[24]  
WAKELING AE, 1991, CANCER RES, V51, P3867
[25]  
WILSON AJ, 1983, REV ENDOCRINE RELATE, V14, P5